GENFIT: Leader of a €2.7 M European-funded EUROTRANSBIO program

Press Release of Bicoll’s OLNORME II partner Genfit SA

The OLNORME II Consortium, for which GENFIT is the leader, is focused on the development of a new class of drug candidates for the prevention and treatment of cardiometabolic diseases with an inflammatory component.
LILLE, France, and CAMBRIDGE, Mass., December 20th, 2010
GENFIT (Alternext: ALGFT; ISIN:FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, will receive €1.2 M as part of the EuroTransBio funding initiative.

Press release of GENFIT, Olnorme II

BIO International 2024June 3-6
+ +